SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells $21,398.22 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 4,486 shares of the stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $4.77, for a total transaction of $21,398.22. Following the transaction, the chief executive officer owned 3,302,839 shares of the company’s stock, valued at $15,754,542.03. This represents a 0.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

SOPHiA GENETICS Price Performance

SOPH opened at $4.96 on Monday. The firm has a 50-day moving average price of $4.87 and a 200-day moving average price of $4.54. SOPHiA GENETICS SA has a twelve month low of $2.58 and a twelve month high of $5.70. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The company has a market capitalization of $339.71 million, a price-to-earnings ratio of -9.73 and a beta of 1.13.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The business had revenue of $21.71 million for the quarter, compared to analysts’ expectations of $21.20 million. Equities analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Guggenheim boosted their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and a consensus target price of $7.00.

Institutional Trading of SOPHiA GENETICS

Institutional investors and hedge funds have recently bought and sold shares of the company. Green Alpha Advisors LLC boosted its holdings in SOPHiA GENETICS by 10.8% in the 4th quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock valued at $213,000 after purchasing an additional 4,444 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of SOPHiA GENETICS by 24.7% in the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the period. Savvy Advisors Inc. purchased a new stake in shares of SOPHiA GENETICS in the third quarter worth $48,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the third quarter worth $49,000. Finally, Perkins Capital Management Inc. bought a new stake in SOPHiA GENETICS during the fourth quarter valued at $49,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.